Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
congrats Ive's, and a good entry point. Myself, i've been here for a while but will hold tight. All the very best on your investment.
i just read. Akers Biosciences (NASDAQ: AKER) was featured this past weekend in an article that appeared in South Jersey's Courier-Post. The article gives a great overview of Akers Biosciences, stating the Company "develops, manufactures and distributes rapid, point-of-care screening and testing products. They include a portable breath alcohol detector, screens for malaria and an allergy to heparin, and a device to determine blood compatibility on a battlefield. Clients include the government of France and the U.S. military." The article goes into further detail about what's driving the Company's jump in sales and its expanding relationship with the U.S. military. Link to article below http://www.courierpostonline.com/article/20140309/BUSINESS02/303090054/-Everything-we-do-helps-people-?nclick_check=1 Clifford, share consolidation took place, 156 - 1, post placement share value at around 520 but this has retraced of late, but still holding. With what is to come, to include for the sales growth, as can be seen from the attached update, then I am happy to hold. All the very best to all here invested.
Thanks Vegas99. What I like about JM is that he wears his heart on his sleeve, calling a good investment good, or even great. On the other hand when something doesn't pan out the way he thought it would, then he tells it as it is, no excuses - tells he made a pigs ear of it - straight talker. So many directors of other co's willing to tell everyone what they think the want to hear, glad to say not here. I certainly like the idea that we have a basket of investments, thus de-risking. Cheers
evening folks, managed to that a position this morning, first of many.
Fourth Pick - Antrim Energy Hello Iano/All, I open the door and look-in just about every day. Don't know if you've read the attached link, but encouraging its on there Hotlist. Lets see if these guys can sort this problem out pronto, or they may just get taken out. http://thesharehub.com/?p=9016
GECR Recommendation - dated 08.01.14 Stance: Buy Target Price: 84p e-Therapeutics has reported that its cancer drug candidate (ETS2101) has shown no drug-related serious adverse events after five dose escalation steps in the phase I brain cancer trial. Accordingly, with an absence of safety concerns to date, the drug discovery and development company plans to evaluate at least one further higher dose level, before reporting the key safety data in 2014 (previously Q4 2013). While there is a slight delay in the reporting of key safety data, we see the lack of drug-related serious adverse events to date as encouraging. With both the company’s leading drug candidates under development (ETS6103 and ETS2101) making good progress, we maintain our stance of buy, with a target price of 84p. Cancer Drug Candidate Update The primary objective of the Phase I trial is to evaluate the safety of ETS2101 and establish an appropriate dose for further studies. Under the protocol, groups of patients are treated at successively higher doses until a maximum tolerated dose is found. Fifteen patients have now completed treatment at doses of up to 24mg/kg body weight. At all doses tested so far, ETS2101 has been generally well tolerated. No objective tumour responses have been reported based on the Response Assessment in Neuro-Oncology (RANO) Working Group Criteria. Detailed data on safety and other endpoints will be submitted to a medical meeting when treatment and follow up of all patients is completed. Forecasts We keep our forecasts unchanged for the time being on the back of this announcement. As the company seeks to make the most of the opportunities provided by its platform and pipeline, we expect to see a further ramp up in investment in discovery and development. For FY14, we are forecasting R&D expenditure to grow to £7.7m, leading to an operating loss of £8.9m. For FY15, we expect the group to maintain its investment momentum and are therefore forecasting an R&D expenditure of £10.0, leading to an operating loss of 11.2m. We expect that the current cash position, together with expected receipts from R&D tax credits and interest, will be sufficient to fund all of its planned discovery and development activities into CY18. Valuation The rNPV for the two drug candidates under development when assuming a 12.5% discount rate is $301 million or 71p. Add on current cash and subtract a perpetuity-estimated G&A cost and this leads us to a target price of 84p. We have been conservative with our assumptions, and see room for significant upside.
Evening D_P, or should i say morning, thanks for the pointer, i'll check it out, but first i'm looking to take a position here. With my recent research into JM i feel that he's well focused on the BioTech-Pharma side, for both growth and that of being bought out. Cheers
Apologies folks, apart from the other errors, the main one being it should have stated - Palatin Technologies Inc. (PTN) -NYSE MKT
This is the vp if anyone's interested, I'd like to hear what you think once you've reviewed and researched yourselves with your own thoughts. The section which i refer starts right on the 36mins time line. http://www.youtube.com/watch?v=gcGR5aon2DU
Hi Vegas99, I haven't managed to take that position yet, need to free up cash from other stocks, but waiting on good news from the one's i have, but i'll hopefully get in before the last week of the month. These boards are about sharing info, and although I wouldn't consider myself as technical as a lot of folks here, including yourself, the time taken along with the good info posted sure helps folk like me. Thanks to all for sharing. This leads me to this potential newbie - I had recently watch a video presentation by Jim Mellon start of December, on that vp he mentioned about a couple of new deals, one was stated as 'Company X' so that got me thinking and researching the possible candidate. Company X had completed phase II and was moving onto phase III, the drug relates to FSD. He is planning to take to company to the IOM, know doubt to do with IP and subsequent taxes and the like. So that got me thinking, did my own research, and from the info it looks like that company may be called Technologies Inc. (PTN) -NYSE MKT - i've taken a position there myself given my own research. As always DYOR - but I think it worth sharing to like-minded folks.
if you want to look at the full Nasdaq application history, then this is the link http://www.nasdaq.com/markets/ipos/company/akers-biosciences-inc-668645-73185?tab=financials
looks like the listing delay is due to no5 amendment re form S-1 having been filed on the 30.12.13. Link - http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=9251672
Thanks for that info.
Looking to invest here, can you let me know which Companies PEBI have in their portfolio, as limited info available. Recently, Jim Mellon advised that he was in the process of taking a company from the states and moving them to the IOM, think that the Company is one which i've recently bought into. Thanks
a possible UK listing due, currently trading on the Nordic exchange, one to check out http://www.bloomberg.com/quote/SOSI:SS
1st post here, given the general market outlook, I have been researching some businesses that the Rothschild's own, or have a stake in, with my focus on mining and resources, this lead me to the below link and to this bb, posted FYI, and i'll look into this for an investment. http://jewishbusinessnews.com/2013/12/01/nathaniel-rothschilds-bumi-plc-december-showdown-postponed-two-weeks-but-still-looming/
see blue along with an encouraging % increase, and that's without any of the usual major rampers, so that in itself looks promising.
Went in and straight back out this morning, had a sl set, just as well! I'm waiting on my new glasses coming, they were meant to ready last week, could sure have done with them on Friday. I think i'll just stick to my usual core of minerals, metals, and uranium stocks for now.
forget that last post of mine, went the other way :(
just read your post, will look into it before Monday, quik pro quo - took a late position in gng just before close on Friday, looks promising, have a look yourself. cheers stephen